Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods

M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema

doi:10.1128/JCM.00872-06

Back

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods

Journal article

Open access

Peer reviewed

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods

M A Pfaller, L Boyken, R J Hollis, S A Messer, S Tendolkar and D J Diekema

Journal of clinical microbiology, Vol.44(10), pp.3533-3538

10/2006

DOI: 10.1128/JCM.00872-06

PMCID: PMC1594802

PMID: 17021079

Files and links (1)

url

https://doi.org/10.1128/JCM.00872-06View

Published (Version of record) Open Access

Abstract

Micafungin is an echinocandin antifungal agent that has recently been approved for the prevention of invasive fungal infection and the treatment of esophageal candidiasis. Prospective sentinel surveillance for the emergence of in vitro resistance to micafungin among invasive Candida sp. isolates is indicated. We determined the in vitro activity of micafungin against 2,656 invasive (bloodstream or sterile site) unique patient isolates of Candida spp. collected from 60 medical centers worldwide in 2004 and 2005. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI) M27-A2 method and used a 24-hour prominent inhibition endpoint for determination of the MIC. Caspofungin was tested in parallel against all isolates. Of 2,656 invasive Candida sp. isolates, species distribution was 55.6% Candida albicans, 14.4% Candida parapsilosis, 13.4% Candida glabrata, 10.1% Candida tropicalis, 2.4% Candida krusei, 1.7% Candida guilliermondii, 0.9% Candida lusitaniae, 0.6% Candida kefyr, and 0.9% other Candida species. Overall, micafungin was very active against Candida (MIC50/MIC at which 90% of the isolates tested are inhibited [MIC90], 0.015/1 microg/ml; 96% inhibited at a MIC of < or =1 microg/ml, 100% inhibited at a MIC of < or =2 microg/ml) and comparable to caspofungin (MIC50/MIC90, 0.03/0.25 mug/ml; 99% inhibited at a MIC of < or =2 microg/ml). Results by species, expressed as MIC50/MIC90 (micrograms per milliliter), were as follows: C. albicans, 0.015/0.03; C. glabrata, 0.015/0.015; C. tropicalis, 0.03/0.06; C. krusei, 0.06/0.12; C. kefyr, 0.06/0.06; C. parapsilosis, 1/2; C. guilliermondii, 0.5/1; C. lusitaniae, 0.12/0.25; other Candida spp., 0.25/1. Although the species distribution varied considerably among the different geographic regions, there was no difference in micafungin activity across the regions. Micafungin has excellent in vitro activity against invasive clinical isolates of Candida from centers worldwide.

Antifungal Agents - pharmacology

Laboratories - standards

Microbial Sensitivity Tests

Lipoproteins - pharmacology

Echinocandins

Peptides, Cyclic - pharmacology

Candida - drug effects

Lipopeptides

Details

Title: Subtitle: Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods
Creators: M A Pfaller - Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
L Boyken
R J Hollis
S A Messer
S Tendolkar
D J Diekema
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.44(10), pp.3533-3538
DOI: 10.1128/JCM.00872-06
PMID: 17021079
PMCID: PMC1594802
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 10/2006
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986255902771

Metrics

26 Record Views

74 Times Cited - Web of Science